CRISPR Ther­a­peu­tics part­ners with siR­NA com­pa­ny, show­ing that gene edit­ing isn’t the on­ly an­swer

4 days ago
R&D
Cell/Gene Tx

RFK Jr. spars with sen­a­tors over re­search cuts, HHS bud­get plan

4 days ago
Pharma
FDA+

Makary, Prasad spell out FDA ground rules for fu­ture Covid vac­cine ap­provals

5 days ago
FDA+
Coronavirus

Tour­ma­line Bio's heart drug cuts in­flam­ma­tion as it seeks to com­pete with No­vo, CSL's as­sets 

5 days ago
R&D

SV Health’s $269M de­men­tia fund; Schrödinger lays off 7% of staff

5 days ago
News Briefing

Up­dat­ed: Trump ad­min­is­tra­tion re­veals 'most fa­vored na­tion' drug price coun­try tar­gets

5 days ago
Pharma
Law

Ex­clu­sive: Weight loss start­up Cal­i­brate swaps CEOs in lat­est lead­er­ship shake­up

5 days ago
People
Startups

Ex­clu­sive: Op­tura rais­es $6.5M to help eval­u­ate health­care AI pro­grams

5 days ago
Financing
Health Tech

Ex­clu­sive: At-home screen­ing start­up Repe­rio Health rais­es $14M

5 days ago
Financing
Diagnostics

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

5 days ago
Bioregnum
Special

Pfiz­er joins PD-1xVEGF race with $1.25B up­front to Chi­nese biotech 3SBio

5 days ago
Deals
China

Retro Bio­sciences inks blood dis­or­der deal as Sam Alt­man-backed biotech seeks $1B in funds

5 days ago
Startups
Deals

Why Re­gen­eron is buy­ing 23andMe

5 days ago
Deals

Ste­lara biosim­i­lars look to gain trac­tion, helped by re­cent lessons from Hu­mi­ra

5 days ago
Pharma

Boehringer In­gel­heim’s late-stage da­ta for lung dis­ease can­di­date un­der­whelm some an­a­lysts

5 days ago
R&D

Prime Med­i­cine side­lines on­ly clin­i­cal pro­gram, re­places CEO and lays off some staff

5 days ago
People
R&D

In­tel­li­a's CRISPR ther­a­py like­ly caus­es 'per­ma­nen­t' gene knock­down in AT­TR amy­loi­do­sis

5 days ago
R&D
Pharma

David Liu, Sam Stern­berg un­veil new way to in­sert big genes in hu­man cells

6 days ago
R&D
Cell/Gene Tx

Io­n­is de­tails late-stage da­ta for heart drug; Ar­ma­ta’s promis­ing staph in­fec­tion ther­a­py

6 days ago
News Briefing

Re­gen­eron plans to buy 23andMe for $256M

6 days ago
Deals
Pharma

Ex­clu­sive: Cell­Cen­tric col­lects $120M to treat mul­ti­ple myelo­ma with a cap­sule

6 days ago
Financing
Startups

Ap­n­imed posts first set of Phase 3 sleep ap­nea re­sults, aims for ap­proval fil­ing in 2026

6 days ago
Startups
R&D

Up­dat­ed: FDA ap­proves No­vavax's Covid vac­cine af­ter six-week de­lay, but for a small­er pop­u­la­tion

6 days ago
Pharma
FDA+

What we know about ‘most fa­vored na­tion’; GSK’s $1.2B MASH deal; Bay­er de­tails staff cuts; and more

Last week
Weekly
First page Previous page 123456 Next page Last page
A service from the Financial Times